Xenon tumbles on voluntary psychiatry hold, but analysts confident in $2B epilepsy opportunity

As Xenon Pharmaceuticals announced that azetukalner has reached the FDA for focal seizures, the company also disclosed the emergence of psychosis adverse events in psychiatric trials of the drug, triggering a temporary pause.